Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Abstract Highlights from EHA 2022 : A Spotlight on CLL

July 26, 2022 | CLL, Medscape Oncology, haematology, medical education, oncology 

- PMLiVE

Spotlight on CLL

Ahead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Prof John Gribben, UK, on the most important abstracts to look out for in CLL. Here are some of the highlights:

  1. Big interest in combining ibrutinib and venetoclax with two studies reported, both considering eradicating minimal residual disease (MRD) and how important that is:
    • Ph 3 FLAIR – interim data – at the 2-year mark when patients are discontinuing treatment, 89% of those patient’s bone marrow was MRD negative and 97% of patient’s blood was negative. This wasn’t seen with ibrutinib monotherapy, showing the strength of adding venetoclax to the combination.
    • Ph 2 CAPTIVATE with different treatment arms; some fixed duration and some driven by the endpoint. Translational data reported on the dynamics of looking at MRD, what cells are left, and do they differ – are we selecting out resistant variants? All important questions being addressed.
    • Combinations are being submitted for approval with it now being important to understand who the suitable patient is compared to the other available choices.
  2. Six-year follow-up data with venetoclax monotherapy in patients with 17p deletion – ORR approx. 77%, median OS >5yrs which is a great advantage for this patient population compared to the past, and median PFS of 28 months. Although we are moving beyond venetoclax monotherapy, this shows the level of efficacy that is being achieved.
  3. Update on the Ph 2 BRUIN study with pirtobrutinib and the patients with CLL who have had a median of 3 prior lines of therapy, meaning they are already heavily pre-treated with 86% having received a prior BTK inhibitor. Good responses are seen and now waiting to see how durable these responses are in terms of longer follow-up to see the long-term benefit.

You can also watch the full video here

About Medscape:
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide. Medscape is the leading online global destination for physicians and healthcare professionals, providing over 5 million members with the latest medical news, expert opinion, and precision education (CME and CPD) to improve clinical practice and advance health outcomes. Medscape’s unrivalled membership reach and therapeutic expertise deliver education across 30+ specialties in 40+ learning formats, using the latest digital and live technology.

This content was provided by Medscape Education

Company Details

Medscape Logo

Medscape Education

Email
Website

 Latest Content from  Medscape Education 

Why Sleep Health is the Missing Link in Women’s Wellness

While obstructive sleep apnea (OSA) affects approximately 32% of US adults—nearly 80 million people—it remains an "epidemic hiding in plain sight". Perhaps most staggering is that 90% of women with...

The Heart and Mouth Connection Every Woman Needs to Know

For decades, modern medicine has treated the mouth and the body as separate entities. But for Dr. Nieca Goldberg, a renowned cardiologist, and Dr. Maria Ryan, Chief Clinical Officer at...

Uncovering Inequities in Alzheimer’s Disease Screening and Care

  On December 5, MAPS hosted an educational webinar exploring recent research in Alzheimer’s disease (AD) screening, testing, and treatment. Experts from Komodo Health and Medscape shared findings from their...

Where Are We Today With Artificial Intelligence (AI) in Rare Disease Diagnosis and Care?

Discover how AI-powered tools are transforming rare disease diagnosis, patient care, and clinical decision-making.

Does Rare Disease Education Work?

For a child with a rare disease, a doctor’s continuing education can end a years-long diagnostic odyssey and unlock access to vital care.

From Genetic Puzzles to Precision Therapeutics

How was a new rare disease discovered through Singapore’s Undiagnosed Disease Program? And how will technology allow us to change how we discover rare diseases in the future? Read more...

Medscape and the GNNRD: Empowering Nurses With a Rare Disease Education Series

Nurses play a vital and multifaceted role in rare disease care, providing consistent patient support, education, and care coordination, and ongoing education is essential to empower them to meet the...

What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?

Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We...

“CGM Sweet Talk With the Sugar Queens” Takes Silver at the 2025 Digital Health Awards

Medscape Education’s dynamic educational series, CGM Sweet Talk With the Sugar Queens, has earned a Silver Award in the Video Series (Digital Health Media / Publications) category at the 2025...

Medscape at ASH 2025: Landmark Value Through the Medscape AI Debut and Five Educational Symposia

For decades, Medscape has been the brand physicians trust. Now, Medscape is forging a new path into the future at ASH 2025 with the launch of Medscape AI — the...